Two vote system accelerates the shuffle of medicine circulation industry and forces the transformation and upgrading of pharmaceutical enterprises

As an important part of the national economy, in the past five years, China's pharmaceutical industry has developed rapidly and its market scale has been expanding In this context, the sales scale of pharmaceutical products is steadily expanding It is reported that in 2016, China's total sales of pharmaceutical products reached 1839.3 billion yuan, a year-on-year increase of 10.4% after deducting incomparable factors, and the growth rate increased by 0.2 percentage points over the previous year With the aging of the population, the opening of the two child policy, the people's attention to health and other factors, the overall scale of China's pharmaceutical market will be further increased For the pharmaceutical circulation industry, the expansion of pharmaceutical commodity market will bring huge dividends, and pharmaceutical circulation enterprises will also benefit a lot However, the problems in the pharmaceutical circulation industry have also attracted the attention of the government and relevant departments I learned that before the two vote system, the circulation of Chinese medicine was complex From the manufacturer to the hospital or drugstore, through layers of agents, through three, four or even more tickets in the middle, there is a huge difference between the factory price and the final sales price, "affiliation", "walking ticket" and other illegal phenomena are widespread Compared with the developed and mature pharmaceutical distribution market in the United States, China's pharmaceutical distribution market has the characteristics of low concentration and low efficiency Such characteristics bring about the current situation of vicious competition and disordered management, and also directly lead to the low efficiency of Chinese pharmaceutical distribution enterprises In order to standardize the order of drug circulation, compress the links of drug circulation and purify the environment of drug circulation, on May 1, 2016, the state encouraged the pilot cities of comprehensive medical reform to implement the two vote system on the basis of the full implementation of "replacing business tax with value-added tax" On January 9, 2017, the national health and Family Planning Commission issued the implementation opinions on the implementation of the "two vote system" in the procurement of public medical institutions (Trial), encouraging other regions to implement the two vote system, and striving to be fully implemented in the country by 2018 The implementation of the two vote system means that there will be a rapid reduction in the number of passes and price increases in the circulation link The pharmaceutical circulation industry will be more transparent and the profits will tend to be standardized This will increase the operating pressure of small-scale pharmaceutical circulation enterprises, reduce their profit space and force them to integrate Affected by this, the wave of merger and reorganization in the pharmaceutical circulation industry will come, the industry concentration is expected to significantly increase, and the new pattern will be re established According to the analysis of relevant experts, the implementation of the two vote system means the improvement of the environment for the industry For large-scale circulation enterprises, it will be good, and the sales outsourcing Organization (CSO) will usher in development opportunities However, the complexity lies in the difficulties of industry integration, distribution and advance payment In addition, Zhao Qiaomin, an analyst with Guangzhou Hengsheng pharmaceutical industry, said that although the two vote system does not have a great impact on large enterprises, it has a greater pressure on smaller pharmaceutical distribution enterprises According to Zhao Qiaomin's analysis, due to the characteristics of low barriers to entry, fierce competition and low gross profit margin (generally 6% - 8%), scale has become an important competitive advantage Compared with small-scale pharmaceutical circulation enterprises, large enterprises have greater advantages in both distribution network and capital strength, and can reduce operating costs and increase customer stickiness Shi lichen, the founder of the third-party medical service platform, gives relevant suggestions In China's complex medical circulation market, private pharmaceutical circulation enterprises have a larger development space, which is regional terminal services and grass-roots medical market Small and medium-sized enterprises can be based on their own business development pattern of regional terminal services and basic medical market layout, and even compete for the share of state-owned pharmaceutical distribution enterprises in the upstream after the development to a certain extent However, Mr Shi also pointed out that small and medium-sized pharmaceutical distribution enterprises need to be stronger before they can be bigger if they want to be stable and based on regional terminal services and grass-roots pharmaceutical markets That is to say, to achieve the degree that others can't replace only cooperation, and to become bigger is to rely on their own strong advantages, so as to occupy the market share of other businesses The implementation of the two vote system will certainly lead to the reshuffle of the pharmaceutical distribution industry, and will also have a huge impact on the pharmaceutical distribution enterprises Regardless of the size of the enterprise, merger and reorganization or not, what the enterprise has to do is to actively transform and upgrade while complying with the policy This requires pharmaceutical distribution enterprises to recognize their own positioning, analyze their strengths and weaknesses, and actively seek cooperation between enterprises, so as to be able to deal with the industry reshuffle with a calm attitude and build a core advantage that can not be surpassed by competitors Teach you to use app to seize the opportunity of pharmaceutical machine